What Is Tetrapeptide-21? Definition and What Research Reports

Definition

Tetrapeptide-21 is the ingredient-nomenclature name for a synthetic peptide built from four amino acid residues — glycine, glutamic acid, lysine and glycine — and usually written in single-letter code as GEKG. It is a laboratory-synthesised molecule rather than a hormone, a drug or an extract, and it sits in the same broad descriptive family as other numbered cosmetic peptides (tetrapeptide-2, tripeptide-1, palmitoyl pentapeptide-4 and so on), where the number is an indexing convention rather than a statement about potency or function. In the published literature the compound appears under both names: some papers use the sequence label "tetrapeptide GEKG" and others use "tetrapeptide-21," and readers comparing sources should treat the two as referring to the same four-residue sequence.

What class of molecule it is

Tetrapeptide-21 is a short linear oligopeptide. At four residues it is far too small to fold into a stable three-dimensional structure the way a protein does, and — like most short peptides — it is hydrophilic and carries charged side chains (the glutamate carboxyl group and the lysine amine). Those properties matter more than they might seem: they are precisely why so much of the research attached to this molecule is about getting it into skin rather than about what it does once it is there. Small, charged, water-loving molecules do not passively cross the stratum corneum easily, and formulation science has repeatedly treated GEKG as a model compound for that problem.

Naming and identifiers

How the term is used in peptide research

Three usages dominate. First, as a formulation model: because GEKG is small, polar and well characterised, it has been used to test whether chemical penetration enhancers or colloidal carriers can move a hydrophilic peptide across skin barriers. Second, as a delivery-vehicle payload: newer work has loaded it into hydrogel systems intended to release it over time rather than all at once. Third, as one member of a panel of bioactive peptides screened against cultured skin cells, where researchers compare several short peptides side by side for effects on cell viability and on the expression of extracellular-matrix genes such as collagen and elastin.

Notably, the term is not used as a clinical or pharmaceutical drug name. There is no approved medicine called tetrapeptide-21, and material sold under that label for laboratory work is generally handled as a research or cosmetic-ingredient chemical. Anyone reading the literature should expect in vitro cell work, ex vivo skin models and formulation chemistry — not phase-structured human trials.

What the Published Literature Reports

The evidence base under this name is small and preclinical. What follows summarises the scope of specific published reports; it is a description of what researchers examined, not a statement about outcomes in people.

Dermal delivery with enhancers and colloidal carriers

A 2018 paper in the European Journal of Pharmaceutical Sciences, the third in a series on dermal peptide delivery, examined tetrapeptide GEKG specifically in the context of enhancer molecules and colloidal carrier systems (PMID 30165235). The study sat within a programme of work comparing how different formulation strategies affect the movement of small hydrophilic peptides into skin, and it is the reason GEKG is frequently cited as a test case in skin-penetration discussions (PMID 30165235).

Hydrogels for sustained delivery

A later report in the International Journal of Pharmaceutics described elastin-derived peptide hydrogels developed for the sustained dermal delivery of tetrapeptide-21, meaning the peptide was the payload rather than the object of a biological efficacy test (PMID 41421628). This is a formulation-engineering line of work: researchers built a carrier material and characterised how it handled the peptide over time (PMID 41421628).

Peptides in cultured dermal fibroblasts

A 2025 in vitro study in Molecules examined injectable platelet-rich fibrin combined with bioactive peptides and reported on dermal fibroblast viability and extracellular matrix gene expression in cell culture (PMID 40871567). That design — cultured human skin cells, viability assays and matrix gene readouts — is the standard early screening format in which short cosmetic peptides are evaluated, and its findings apply to cells in a dish rather than to intact human skin (PMID 40871567).

What the literature does not establish

• No human clinical efficacy claims can be drawn from the records above: the cited work is formulation science and cell culture, and the study designs were not randomised human trials (PMID 40871567).
• No systemic pharmacology. The published work located under this name addressed dermal delivery and skin-cell endpoints, not injection, absorption into the bloodstream or systemic effects (PMID 30165235).
• No dosing framework. Because the cited papers are delivery and in vitro studies, they do not support any human dose, concentration schedule or regimen, and none is described on this page (PMID 41421628).

Adverse Events: What Studies Report

The verified papers indexed under this peptide name were not designed as safety or tolerability trials. The 2025 in vitro work reported cell-level outcomes including dermal fibroblast viability in culture, which is a cytotoxicity-adjacent measure rather than a clinical adverse-event record (PMID 40871567). The delivery-focused papers characterised formulation and penetration behaviour rather than human side-effect profiles (PMID 30165235, PMID 41421628). In short: within this evidence set there is no published human adverse-event dataset to summarise, and the absence of reported harms in preclinical formulation studies is not the same as demonstrated safety.

Related glossary terms

• Tetrapeptide — the parent class; any four-residue peptide.
• Signal peptide (cosmetic usage) — informal label for short peptides studied for effects on matrix gene expression in skin cells.
• Penetration enhancer — an excipient used to increase movement of a compound across the stratum corneum, one of the variables examined in the 2018 GEKG study (PMID 30165235).
• Hydrogel carrier — a water-swollen polymer network used to hold and release a payload, the approach taken in the elastin-derived hydrogel report (PMID 41421628).

Bottom line

Tetrapeptide-21 is best understood as a named four–amino-acid sequence (GEKG) that appears in dermatological formulation research and in vitro skin-cell screening. The published record attached to it is narrow, recent and preclinical, concentrating on how the molecule can be delivered into skin and how short peptides behave in fibroblast culture. This page is for educational purposes only and is not medical advice; consult a licensed physician or qualified healthcare professional about any health decision. Nothing here describes a protocol, and no human dosing information exists in the cited literature to report.

References

• Dermal peptide delivery using enhancer molecules and colloidal carrier systems. Part III: Tetrapeptide GEKG (European Journal of Pharmaceutical Sciences, 2018)
• Synergistic Effects of Injectable Platelet-Rich Fibrin and Bioactive Peptides on Dermal Fibroblast Viability and Extracellular Matrix Gene Expression: An In Vitro Study (Molecules, 2025)
• Elastin-derived peptide hydrogels for sustained dermal delivery of tetrapeptide-21 (International Journal of Pharmaceutics, 2026)